BLAINJECTIONSOLUTIONPriority Review
Approved
Dec 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
5/8 — Partial
Priority Review
ELZONRIS (tagraxofusp) by Stemline Therapeutics is cd123 interactions [moa]. Approved for acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm. First approved in 2018.
Drug data last refreshed 21h ago
Mechanism of Action
CD123 Interactions
Pharmacologic Class:
CD123 Interaction
Worked on ELZONRIS at Stemline Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.